Optimization with levosimendan improves outcomes after left ventricular assist device implantation

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Pharmacology

Background:

• Left ventricular assist device (LVAD) implantation is a critical intervention for advanced heart failure.
• Optimizing patient hemodynamics and end-organ function preoperatively is crucial for successful LVAD outcomes.
• The role of specific inotropic agents like levosimendan in this setting requires further investigation.

Purpose of the Study:

• To assess the hemodynamic effects of preoperative levosimendan infusion in patients undergoing LVAD implantation.
• To evaluate the impact of levosimendan on early and late prognoses, including right ventricular failure (RVF) and mortality.
• To determine the safety profile of levosimendan in this patient population.

Main Methods:

• A prospective study included 85 adult patients with dilated or ischemic cardiomyopathy undergoing LVAD implantation.
• Patients were divided into two groups: Group A received levosimendan plus other inotropes (n=58), and Group B received other inotropes alone (n=27).
• Levosimendan was administered at 0.1 µg/kg/min for up to 48 hours. Primary outcome was early RVF; secondary outcomes included mortality, need for RVAD, late RVF, and end-organ function recovery.

Main Results:

• Patient characteristics were similar between groups.
• No significant differences were observed in early mortality, RVF, need for RVAD, cardiopulmonary bypass time, or ICU stay.
• Survival rates at 30 days, 1 year, and 3 years, as well as freedom from late RVF, were comparable. Levosimendan was safe and well-tolerated.

Conclusions:

• Preoperative levosimendan therapy in LVAD patients is safe and well-tolerated.
• Combined therapy with inotropes and levosimendan significantly improves end-organ function recovery.
• Levosimendan does not appear to negatively impact early hemodynamic outcomes or increase the risk of RVF in LVAD recipients.